| Id |
Subject |
Object |
Predicate |
Lexical cue |
| TextSentencer_T1 |
0-154 |
Sentence |
denotes |
Synthetic sulfogalactosylceramide (sulfatide) and its use for the mass spectrometric quantitative urinary determination in metachromatic leukodystrophies. |
| T1 |
0-154 |
Sentence |
denotes |
Synthetic sulfogalactosylceramide (sulfatide) and its use for the mass spectrometric quantitative urinary determination in metachromatic leukodystrophies. |
| TextSentencer_T2 |
155-326 |
Sentence |
denotes |
3-O-Sulfogalactosylceramides (sulfatides) accumulate in the genetic disease metachromatic leukodystrophy which is due to a defect in the catabolic enzyme, arylsulfatase A. |
| T2 |
155-326 |
Sentence |
denotes |
3-O-Sulfogalactosylceramides (sulfatides) accumulate in the genetic disease metachromatic leukodystrophy which is due to a defect in the catabolic enzyme, arylsulfatase A. |
| TextSentencer_T3 |
327-428 |
Sentence |
denotes |
Clinical diagnosis is usually confirmed by in vitro enzymatic deficiency of arylsulfatase A activity. |
| T3 |
327-428 |
Sentence |
denotes |
Clinical diagnosis is usually confirmed by in vitro enzymatic deficiency of arylsulfatase A activity. |
| TextSentencer_T4 |
429-571 |
Sentence |
denotes |
The diagnosis may be complicated because of arylsulfatase A pseudo-deficiencies and another cause of MLD, sphingolipid activator B deficiency. |
| T4 |
429-571 |
Sentence |
denotes |
The diagnosis may be complicated because of arylsulfatase A pseudo-deficiencies and another cause of MLD, sphingolipid activator B deficiency. |
| TextSentencer_T5 |
572-698 |
Sentence |
denotes |
As large quantities of sulfatides can be found in the urine in this disease, sulfatiduria appears as an extremely useful test. |
| T5 |
572-698 |
Sentence |
denotes |
As large quantities of sulfatides can be found in the urine in this disease, sulfatiduria appears as an extremely useful test. |
| TextSentencer_T6 |
699-846 |
Sentence |
denotes |
As recently enzyme replacement is underway, the quantitative determination, using an internal standard, appears particularly useful as a follow-up. |
| T6 |
699-846 |
Sentence |
denotes |
As recently enzyme replacement is underway, the quantitative determination, using an internal standard, appears particularly useful as a follow-up. |
| TextSentencer_T7 |
847-1037 |
Sentence |
denotes |
Thus a non-physiological sulfatide was synthesized for this purpose, i.e. 3-O-sulfo-beta-D-C17 galactosylceramide (3-O-Sulfo-D: -Galactosyl-beta1'-->1-N-Heptadecanoyl-D-erythro-Sphingosine). |
| T7 |
847-1037 |
Sentence |
denotes |
Thus a non-physiological sulfatide was synthesized for this purpose, i.e. 3-O-sulfo-beta-D-C17 galactosylceramide (3-O-Sulfo-D: -Galactosyl-beta1'-->1-N-Heptadecanoyl-D-erythro-Sphingosine). |
| TextSentencer_T8 |
1038-1170 |
Sentence |
denotes |
It has been prepared through condensation of an azidosphingosine derivative with a protected D-galactopyranosyltrichloroacetimidate. |
| T8 |
1038-1170 |
Sentence |
denotes |
It has been prepared through condensation of an azidosphingosine derivative with a protected D-galactopyranosyltrichloroacetimidate. |
| TextSentencer_T9 |
1171-1241 |
Sentence |
denotes |
Reduction of the azide was followed by acylation of a C-17 fatty acid. |
| T9 |
1171-1241 |
Sentence |
denotes |
Reduction of the azide was followed by acylation of a C-17 fatty acid. |
| TextSentencer_T10 |
1242-1453 |
Sentence |
denotes |
The key step was achieved by selective sulfation of the desired hydroxyl group on the sugar residue of the galactosylceramide using the stannylene methodology to give a 3'-sulfated beta-galactosyl C-17 ceramide. |
| T10 |
1242-1453 |
Sentence |
denotes |
The key step was achieved by selective sulfation of the desired hydroxyl group on the sugar residue of the galactosylceramide using the stannylene methodology to give a 3'-sulfated beta-galactosyl C-17 ceramide. |